ISCTM Tackles De-Risking Phase 3 Investments in CNS Drug Development
(firmenpresse) - PHILADELPHIA, PA -- (Marketwired) -- 08/13/13 -- Over the past several years, R&D investment has been moving out of CNS drug development and into disease areas with simpler human biology and genetics, which offer greater promise for the identification of relevant targets and the advancement of specific pharmacological therapies. Since R&D funding, even in some of the largest pharmaceutical companies, is limited and competition for dollars can be intense, many companies have shifted their portfolios towards other areas of medical need such as diabetes, oncology and inflammation. How might those of us working on CNS disorders help to reverse this trend? Many of our attempts to improve the success of our CNS development programs have been directed at the challenges of Phase 3 design and conduct. However, drug discovery and research may provide important solutions. If early phase development can resolve key risks, this will significantly increase the likelihood of late phase development success.
Recognizing its paramount importance to the field of CNS drug development, this issue will be the focus of the , 30 September - 2 October, 2013, Philadelphia, PA. meetings provide a unique opportunity for all stakeholders, from FDA, NIH to Industry and Academic drug developers and payers, to convene in a precompetitive, non-commercial environment to address these developmental challenges. Session will highlight the fundamentals of early phase development and speak to the process of moving from early phase to full development, and the operational complexities associated with executing global development programs.
ISCTM will also initiate two new working groups: one on International Clinical Trials (focus on Harmonization issues), chaired by Richard Keefe, PhD and Amir Kalali, MD and another Initiating Innovations in CNS Clinical Trials, chaired by Gary Sachs, MD. These will join workshops presented by ongoing working groups on Adaptive Design, Biomarkers, Cognitive Assessment in Alzheimer's Disease, Negative Symptoms and Suicidal Ideation and Behavior.
If you are not familiar with the ISCTM, we invite you to review the Society's Meeting Library, where video and presentations from the are available for public viewing. We would also draw your attention to the page which gives detail on activities of the groups.
In conjunction with the Scientific Meeting, ISCTM will host a poster session.
Deadline for abstract submission is 26 August.
Early registration discounts are available through Friday, August 16.
Details:
Contact:
Carlotta D. McKee
ISCTM, Executive Director
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 13.08.2013 - 10:05 Uhr
Sprache: Deutsch
News-ID 1254290
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
PHILADELPHIA, PA
Phone:
Kategorie:
Surgery & Treatments
Anmerkungen:
Diese Pressemitteilung wurde bisher 193 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ISCTM Tackles De-Risking Phase 3 Investments in CNS Drug Development
"
steht unter der journalistisch-redaktionellen Verantwortung von
ISCTM (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
